This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study for Absorption of Intranasal Epinephrine Compared to Conventional Intramuscular Epinephrine (Epinephrine)

This study has been completed.
Mahidol University
Information provided by (Responsible Party):
Pakit Vichyanond, MD, Siriraj Hospital Identifier:
First received: January 19, 2011
Last updated: September 12, 2011
Last verified: September 2011
This study is a preliminary report of pharmacokinetic data of epinephrine administered via intranasal route (IN) comparing with intramuscular (IM) route in healthy adult volunteers.

Condition Intervention
Anaphylaxis Drug: Epinephrine

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of Absorption of Epinephrine Into the Circulation After Epinephrine Intranasal Spray Administration and After Intramuscular Injection

Resource links provided by NLM:

Further study details as provided by Pakit Vichyanond, MD, Siriraj Hospital:

Primary Outcome Measures:
  • Composite of Pharmacokinetics of epinephrine [ Time Frame: predose, 5 , 10, 15, 20, 30, 45, 60, 90, 120, 180 minutes post-dose ]
    Cmax, Area Under Curve, Tmax of epinephrine compare between 0.3 mg intramuscular and 5 mg intranasal route

Secondary Outcome Measures:
  • Numbers of participants with adverse events as a measure of safety and tolerability [ Time Frame: 1 year ]
    Any side effects from such administration such as bad smelling, sorethroat.

Estimated Enrollment: 12
Study Start Date: July 2010
Study Completion Date: September 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: epinephrine IN, epinephrine IM, saline IN
  1. Intranasal saline
  2. Intramuscular epinephrine
  3. Intranasal epinephrine
Drug: Epinephrine
  1. Intranasal epinephrine 5 mg /spray
  2. Intramuscular epinephrine 0.3 mg
  3. Intranasal saline spray
Other Name: adrenaline

Detailed Description:
Patients are reluctant to use Epipen® on emergency basis, perhaps because of improperly training, hesitancy and fear of needle. Other route of administration of epinephrine (EPI) may be more benefit such as intranasal route.

Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy subjects
  2. 18-30 years-old

Exclusion Criteria:

  1. Pregnancy
  2. Subjected who use current medication that interfere with result of plasma epinephrine level such as pseudoephedrine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01432522

Facaulty of Medicine, Siriraj Hospital
Bangkok, Thailand, 10700
Sponsors and Collaborators
Siriraj Hospital
Mahidol University
Study Director: Pakit Vichyanond, MD. Siriraj medical school, Mahidol Univrsity
  More Information

Responsible Party: Pakit Vichyanond, MD, Professor of Pediatrics, Siriraj Hospital Identifier: NCT01432522     History of Changes
Other Study ID Numbers: 078/2550
Study First Received: January 19, 2011
Last Updated: September 12, 2011

Keywords provided by Pakit Vichyanond, MD, Siriraj Hospital:
Intranasal epinephrine
Plasma epinephrine level

Additional relevant MeSH terms:
Hypersensitivity, Immediate
Immune System Diseases
Epinephryl borate
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents processed this record on August 18, 2017